Fluvastin therapy affects TAFI concentration in kidney transplant recipients
暂无分享,去创建一个
[1] J. Małyszko,et al. Simvastain Affects TAFI and Thrombomodulin in CAPD Patients , 2001, Thrombosis and Haemostasis.
[2] M. Myśliwiec,et al. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] P. Ridker,et al. Soluble P-Selectin and the Risk of Future Cardiovascular Events , 2001, Circulation.
[4] M. Wolzt,et al. Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia , 2001, Thrombosis and Haemostasis.
[5] F. Rosendaal,et al. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.
[6] G. Habib,et al. Fluvastatin Decreases Soluble Thrombomodulin in Cardiac Transplant Recipients , 2000, Thrombosis and Haemostasis.
[7] J. Harenberg,et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. , 1999, Thrombosis research.
[8] F. Locatelli,et al. Morbidity and Mortality on Maintenance Haemodialysis , 1998, Nephron.
[9] M. Boffa,et al. A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor* , 1998, The Journal of Biological Chemistry.
[10] B. Fagerberg,et al. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men , 1998, Journal of hypertension.
[11] J. Morser,et al. Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activable Fibrinolysis Inhibitor* , 1998, The Journal of Biological Chemistry.
[12] T. Hayek,et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. , 1998, Journal of cardiovascular pharmacology.
[13] M. Boffa,et al. Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis , 1997, Thrombosis and Haemostasis.
[14] G. Lip,et al. Hypothesis: is soluble P-selectin a new marker of platelet activation? , 1997, Atherosclerosis.
[15] J. Małyszko,et al. The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. , 1996, Transplantation.
[16] D. Pawlak,et al. Platelet aggregation and peripheral serotonergic system in kidney transplant recipients treated with cyclosporine. , 1996, Transplantation proceedings.
[17] R. Stein,et al. Comparison of ST-segment/heart rate slope analysis with standard ST-segment measurement criteria to outcome of exercise thallium-201 imaging. , 1995, The American journal of cardiology.
[18] R. Goldberg,et al. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. , 1995, The American journal of cardiology.
[19] D. Di Landro,et al. Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. , 1995, Transplantation.
[20] M. H. Gault,et al. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. , 1995, Nephron.
[21] R. Knöfler,et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. , 1994, Thrombosis research.
[22] S. Knechtle,et al. Hyperlipidemia and transplantation: etiologic factors and therapy. , 1992, Journal of the American Society of Nephrology : JASN.
[23] P. Newman,et al. Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. , 1990, The Journal of biological chemistry.
[24] J. Loscalzo,et al. Lipoprotein(a). A unique risk factor for atherothrombotic disease. , 1990, Arteriosclerosis.
[25] I. Kovács,et al. Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients. , 1990, Transplantation.
[26] K. Schrör. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents. , 1990, Eicosanoids.
[27] Z. Varghese,et al. Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] T. Lerut,et al. THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS , 1985, The Lancet.